Targets in Triple-Negative Breast Cancer
Fabrice Andre, MD, PhD, says that there are no targets in triple-negative breast cancer in accordance with the current vision of the disease.
Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, gives an overview of targets in triple-negative breast cancer (TNBC).
With the current vision of targets in breast cancer (genetic alterations located on a kinase, there are no targets in TNBC, Andre says. As this is a very specific view of what to target, there is no clinical research to validate any other way.
Clinical Pearls
Andre believes that immunotherapies, modulation of DNA repair, modulation of kinases, and a combination of a kinase inhibitor and modulators of DNA repair are all interesting areas that deserve further analysis.
- There is no target in TNBC with the current vision of breast cancer
- In TNBC, immunotherapies, modulation of DNA repair, and modulation of kinases are all interesting areas to be explored further
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
